July 23, 2024
SSI Strategy LLC, a global leader in strategic consulting for life sciences, is pleased to announce a partnership with MPS Metalmind AB, an innovator in AI services. This collaboration marks a significant milestone for SSI Strategy, emphasizing commitment to leveraging cutting-edge artificial intelligence to drive innovation and enhance business capabilities.
Through this partnership, SSI Strategy will leverage Metalmind’s advanced capabilities in natural language processing (NLP) and large language models (LLMs) to enhance our service delivery. This will enable us to:
Johan Strömquist, Chief Innovation Officer at SSI Strategy says: “Partnering with Metalmind opens new possibilities for SSI Strategy, enhancing our service offerings and strengthening our market position. This collaboration positions SSI Strategy as a leader in AI-supported consulting services and allows us to scale to meet growing client demands without compromising quality.”
About SSI Strategy LLC
SSI Strategy LLC is a global strategic consulting firm dedicated to supporting the medical office needs of life science organizations. Headquartered in Parsippany, NJ, SSI Strategy helps clients maximize therapeutic value from translational development to product launch, expertly navigating the complexities of bringing important therapeutics to market.
About MPS Metalmind AB
MPS Metalmind AB is a pioneering AI service provider specializing in NLP solutions, knowledge graphs, document generation, and conversational agents. Based in Kista, Sweden, Metalmind is committed to delivering innovative AI technologies that transform business processes and enhance decision-making capabilities.
June 24, 2025
Alithea Genomics, a pioneering biotech company based in Switzerland and the USA specializing in high-throughput RNA sequencing solutions, today announ...
June 19, 2025
Alithea Genomics, a pioneering biotech company based in Switzerland and the USA specializing in scalable RNA sequencing solutions, today announced the...
June 16, 2025
Fast Track granted for a next-generation, PARP1-selective inhibitor with CNS activity Addresses brain metastases harboring BRCA1/2 and/or HRR alterati...
Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225